Concert Pharma (CNCE) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $103.7M

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of ($0.78), $0.03 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $543 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• OLB Group narrows net loss 50% as revenue falls in Q2 2026